| Ms Patricia K Connors, MA LCSW LMFT CADCIII | |
|
615 S 8th St, Ste G20, Sheboygan, WI 53081-4405 | |
| (920) 457-8866 | |
| (920) 457-8867 |
| Full Name | Ms Patricia K Connors |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 615 S 8th St, Sheboygan, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356327738 | NPI | - | NPPES |
| 39306500 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 3685123 (Wisconsin) | Primary |
| 106H00000X | Marriage & Family Therapist | 12124 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Patricia K Connors, MA LCSW LMFT CADCIII 615 S 8th St, Ste G20, Sheboygan, WI 53081-4405 Ph: (920) 457-8866 | Ms Patricia K Connors, MA LCSW LMFT CADCIII 615 S 8th St, Ste G20, Sheboygan, WI 53081-4405 Ph: (920) 457-8866 |
News Archive
With the nation facing a $9 trillion deficit over the next 10 years, according to government estimates, the future of health care reform depends upon a neglected but critical leg of the equation: cost. Some of the nation's leading experts in health and health care reform will provide insights into this issue when they converge in Nashville Saturday for a nonpartisan public discussion.
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
Variations in regional mortality and spending rates in the US Medicare system are being blurred by inadequate risk adjustment methodology, researchers suggest.
Researchers at the University of Louisville's James Graham Brown Cancer Center have identified for the first time mutations that destabilize a DNA structure that turns a gene off. These mutations occur at four specific sites in what is known as the "hTERT promoter" in more than 75 percent of glioblastomas and melanomas.
› Verified 1 days ago